Will transfer API manufacturing at the site to other facilities within the AMRI network
AMRI will close its Holywell, UK facility with the loss of more than 60 jobs.
The US contract research and manufacturing organisation proposed the closure in February and has now completed consultations with employee representatives at the site in Flintshire, Wales.
The former Excelsyn site, bought by AMRI in 2010, provides chemical development services and small- and large-scale manufacturing services for active pharmaceutical ingredients (API) and intermediates.
AMRI's President and Chief Executive William Marth said: 'This was a difficult decision as it impacts team members who have made valuable contributions to AMRI. We will work diligently to ensure the closing of the Holywell facility goes as smoothly as possible for our customers and employees.'
AMRI will transfer the activities at the Holywell site to other facilities within its network and plans to cease operations at the site by the end of this year.
The closure is expected to affect approximately 62 positions.